|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,026 GBX | +5.94% |
|
+10.72% | +13.45% |
| 11:31pm | Health Care Drops Amid Mixed Earnings -- Health Care Roundup | DJ |
| 10:19pm | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
LONDON (Reuters) - AstraZeneca is looking to partner or sell its anti-infective and neuroscience drugs, since these products are no longer core areas for the British drugmaker, its chief executive said on Thursday.
Pascal Soriot told reporters in a first-quarter conference call that he was investigating all options for the businesses as the drugmaker redeploys resources to the priority areas of oncology, cardiovascular and metabolic diseases, and respiratory and inflammation.
(Reporting by Ben Hirschler; Editing by Mark Potter)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.45% | 219B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B | |
| +2.07% | 117B |
ASTRAZENECA PLC 
By 
